TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06215222

Intervention type: OTHER
Intervention: Microbiota Sampling
Description: We will sample the Saliva, Feces, and intestinal microbiome for genetic microbiome analysis and bacterial isolation

Intervention type: OTHER
Intervention: Microbiota Sampling
Description: We will sample the Saliva, Feces, and intestinal microbiome for genetic microbiome analysis and bacterial isolation
Study: NCT06412419

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnifying Endoscopy and Endoscopic Ultrasonography
Description: The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnifying Endoscopy and Endoscopic Ultrasonography
Description: The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnifying Endoscopy and Endoscopic Ultrasonography
Description: The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnifying Endoscopy and Endoscopic Ultrasonography
Description: The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.
Study: NCT04377334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells
Study: NCT05025735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib.
Study: NCT05874687

Intervention type: DRUG
Intervention: hypotension + treat
Description: Heart Rate and Mean Arterial Pressure (MAP) will be recorded throughout the procedure (every 2 minutes for the first 15 minutes). Ephedrine (in 6 mg increments) will be used as well as the isotonic balanced crystalloid solution to treat hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg (250 mL bolus). The Ephedrine dose will be recorded. Bradycardia, which is defined as a heart rate less than 50 beats per minute, will be treated with intravenous Atropine (0.5 mg).
Study: NCT06239506

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06716827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-bleaching
Description: The whitening trays were custom-made for the fixed appliance patients, and they used them for 2-4 hours each evening after brushing their teeth. In the transparent aligner group, whitening was done using the aligners worn for treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: This group of patients did not undergo any whitening procedures.
Study: NCT06716047

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral administration
Description: Take it directly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral administration
Description: Take it directly
Study: NCT04488224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-X Patient Rotation System
Description: The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-X Patient Rotation System
Description: The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional CBCT scan
Description: A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometrically validated questionnaires
Description: The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometrically validated questionnaires
Description: The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.
Study: NCT06715553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BALANCE Program (Body, Art, Learning, Activities, Nutrition, Creativity, and Education)
Description: Six types of intervention will be done on the patients as follows:~* Psychoeducational intervention program~* Art therapy program~* Bibliotherapy program~* Nutrition program~* Sport activity~* Ping Pong activity
Study: NCT06712810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axl/Mer/CSF1R Inhibitor Q702
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study: NCT06714890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Stimulation
Description: Transcranial Electrical Stimulation Combined with Accommodation-related Visual Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Training
Description: Accommodation-related Visual Training
Study: NCT05193006

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05059951

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Chemotherapy follow the guild line.
Study: NCT04658420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF
Study: NCT04573205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSME-IMMUN Vaccine
Description: 0.5 ml intramuscular injection scheduled in the two different arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN Vaccine
Description: 0.5 ml intramuscular injection scheduled in the two different arms
Study: NCT04791267

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community Health Navigator Program
Description: Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Navigator Program
Description: Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
Study: NCT05024877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Hetrombopag would be given started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stanozolol Tablets
Description: Stanozolol would be given 2mg tid.
Study: NCT02814864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cell (MSC) injections
Description: 12 patients suffering of PRD (LENT-SOMA scale\>2) will receive Mesenchymal Stromal Cell (MSC) injections
Study: NCT06060756

Intervention type: OTHER
Intervention: questionnaires completion
Description: Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):~* Pain-related questionnaire~* Endometriosis-specific questionnaire~* Hospital Anxiety and Depression scale~* Questionnaire McGill on Quality Of Life~* Insomnia-related questionnaire
Study: NCT06033846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: treatment with minocycline combined with first/second-line drugs for autoimmune encephalitis
Study: NCT05147974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DOZE app
Description: Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD.
Study: NCT06409702

Intervention type: DRUG
Intervention: Carfilzomib
Description: Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued

Intervention type: DRUG
Intervention: Daratumumab
Description: 28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued

Intervention type: DRUG
Intervention: Lenalidomide
Description: 28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression

Intervention type: DRUG
Intervention: Dexamethasone
Description: 28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8
Study: NCT05780528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan mobilization
Description: The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumented assisted soft tissue mobilization
Description: the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
Study: NCT06409702

Intervention type: DRUG
Intervention: VRD for first-cycle induction therapy
Description: Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。
Study: NCT05060783

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Serum

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Serum

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Serum

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Urine

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Urine

Intervention type: DIAGNOSTIC_TEST
Intervention: GaGnostic
Description: Urine
Study: NCT05494749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zirconomer
Description: teeth meeting the inclusion criteria are assigned to receive Zirconomer® restorations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVGI-Equia Forte
Description: teeth meeting the inclusion criteria are assigned to receive HVGI-Equia Forte® restorations.
Study: NCT05352906

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular pressure
Description: Measurements of intraocular pressure in millimeter mercury (mmHg).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular pressure
Description: Measurements of intraocular pressure in millimeter mercury (mmHg).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular pressure
Description: Measurements of intraocular pressure in millimeter mercury (mmHg).
Study: NCT06131125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training exercises
Description: This includes plyometric training exercises thrice a week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explosive strength training exercises
Description: this includes explosive strength training exercises thrice a week for 6 weeks
Study: NCT05812339

Intervention type: DEVICE
Intervention: Gastric Alimetry System
Description: Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.

Intervention type: DEVICE
Intervention: Gastric Alimetry System
Description: Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
Study: NCT05393245

Intervention type: DRUG
Intervention: Tiotropium+Olodaterol
Description: Tiotropium+Olodaterol

Intervention type: DEVICE
Intervention: Spiolto Respimat
Description: Spiolto Respimat Inhaler device

Intervention type: DRUG
Intervention: Long-acting muscarinic antagonists (LAMAs)
Description: Long-acting muscarinic antagonists (LAMAs)

Intervention type: DRUG
Intervention: Long-acting β2-agonists (LABAs)
Description: Long-acting β2-agonists (LABAs)
Study: NCT06062017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water and Potassium supplementation
Description: All Participants will be given cases of water and instructed to drink at least an extra 1L per day. Additionally, participants will be given 2000 mg of potassium via potassium citrate powder.
Study: NCT05056896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Capsule taken orally